

## INFORMATION DISCLOSURE STATEMENT

Applicant : Cowing, Carol O.  
 App. No : 09/809,158  
 Filed : March 15, 2001  
 For : METHOD TO ENHANCE THE  
       IMMUNOGENICITY OF AN  
       ANTIGEN  
 Examiner : Karen A. Canella  
 Art Unit : 1643

Mail Stop Amendment  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 3 references to be considered by the Examiner. Also enclosed are 3 references as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: November 18, 2005

By: *[Signature]*

Marina L. Gordey  
 Registration No. 52,950  
 Agent of Record  
 Customer No. 20,995  
 (805) 547-5580

11/22/2005 FMETEK11 00000018 09809158

01 FC:1806

180.00 OP



Docket No.: LANCELL.002CP1

November 18, 2005

Page 1 of 1

Please Direct All Correspondence to Customer Number 20995

## TRANSMITTAL LETTER

### INFORMATION DISCLOSURE STATEMENT

Applicant : Cowing, Carol O.  
App. No : 09/809,158  
Filed : March 15, 2001  
For : METHOD TO ENHANCE THE  
IMMUNOGENICITY OF AN ANTIGEN  
Examiner : Karen A. Canella  
Art Unit : 1643

#### CERTIFICATE OF MAILING

I hereby certify that this correspondence and all  
marked attachments are being deposited with  
the United States Postal Service as first-class  
mail in an envelope addressed to: Mail Stop:  
Amendment, Commissioner for Patents, P.O.  
Box 1450, Alexandria, VA 22313-1450, on

November 18, 2005

(Date)

Marina L. Gordey, Reg. No. 52,950

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
- (X) Listing 3 references.  
(X) Enclosing 3 references.
- (X) A check in the amount of \$180.00 to cover the above fee is enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

\_\_\_\_\_  
Marina L. Gordey  
Registration No. 52,950  
Agent of Record  
Customer No. 20,995  
(805) 547-5580



NOV 21 2005

PTO/SB/08 Equivalent

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*(Multiple sheets used when necessary)*

SHEET 1 OF 1

Application No.	09/809,158
Filing Date	March 15, 2001
First Named Inventor	Cowing, Carol O.
Art Unit	1643
Examiner	Karen A. Canella
Attorney Docket No.	LANCELL.002CPI

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
KAC	3	WO 98/20734	05-22-1998	U.S. Government		

## **NON PATENT LITERATURE DOCUMENTS**

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>

1970438:vr100405

**\*Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**T<sup>1</sup>** - Place a check mark in this area when an English language Translation is attached.



1642  
PATENT

Case Docket No. LANCELL.002CP1  
Date: November 17, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Cowing, Carol O.  
Appl. No. : 09/809,158  
Filed : March 15, 2001  
For : METHOD TO ENHANCE THE  
IMMUNOGENICITY OF AN  
ANTIGEN  
Examiner : Canella, Karen A.  
Group Art Unit : 1642

I hereby certify that this correspondence and all  
marked attachments are being deposited with the  
United States Postal Service as first class mail in  
an envelope addressed to: Commissioner for  
Patents, Mail Stop Amendment, P.O. Box 1450,  
Alexandria, VA 22313-1450, on

November 17, 2004

(Date)

Marina L. Gordey, Reg. No. 52,950


TRANSMITTAL LETTER

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- An Information Disclosure Statement.
- A PTO Form 1449 with eight (8) references.
- The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- Return prepaid postcard.

  
\_\_\_\_\_  
Marina L. Gordey  
Registration No. 52,950  
Agent of Record  
Customer No. 20,995  
(805) 547-5580

**INFORMATION DISCLOSURE STATEMENT**

Applicant : Cowing, Carol O.  
App. No. : 09/809,158  
Filed : March 15, 2001  
For : METHOD TO ENHANCE THE  
IMMUNOGENICITY OF AN ANTIGEN  
Examiner : Canella, Karen A.  
Group Art Unit : 1642

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 8 references that are also enclosed.

This Information Disclosure Statement is being filed before the mailing date of a final action under 37 C.F.R. § 1.113 and before the mailing date of a Notice of Allowance under § 1.311. A certification under 37 C.F.R. § 1.97(e) is set forth below. Thus, no fee is required as set forth in 37 C.F.R. § 1.97(c).

**CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(2)**

I hereby certify that no item of information contained in this Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R.

Appl. No. : 09/809,158  
Filed : March 15, 2001

Docket No. LANCELL.002CP1  
Customer No. 20,995

§ 1.56(c) more than 30 days prior to the filing of this Information Disclosure Statement.



Dated: November 14, 2004


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By: \_\_\_\_\_ 

Marina L. Gordey  
Registration No. 52,950  
Agent of Record  
Customer No. 20,995  
(805) 547-5580

O:\DOCS\MXG\MXG-6309.DOC:vr  
111104



<p style="text-align: right;">FEE FORM PTO-1449</p> <p style="text-align: right;">U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p style="text-align: right;"><i>NOV 22 2004</i> <i>PATENT &amp; TRADEMARK OFFICE</i></p> <p style="text-align: right;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="text-align: right;">(USE SEVERAL SHEETS IF NECESSARY)</p>	<p>ATTY. DOCKET NO. LANCELL_002CP1</p>	<p>APPLICATION NO. 09/809,158</p>
<p>APPLICANT Cowing, Carol O.</p>		
<p>FILING DATE March 15, 2001</p>		<p>GROUP 1642</p>

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
KAC	5	0 308 210	03/22/1989	Europe			
KAC	6	2 145 931	04/11/1985	Great Britain			

**EXAMINER  
INITIALS**

**OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)**

INITIAL		
KAC	7	Enk A.H. et al. 1993 "An essential role of Langerhans cell-derived IL-1 $\beta$ in the initiation of primary immune response in skin," <i>J. Immunol.</i> 150:3698-3704.
KAC	8	Supplemental European Search Report from corresponding application EP 98 91 8392, mailed on October 21, 2004.

O:\DOCS\WXG\WXG-6307.DOC111104

**EXAMINER** \_\_\_\_\_ **DATE CONSIDERED** \_\_\_\_\_

**\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.**

O:DOCS REC'D 12/15/2003  
DEC 15 2003  
U.S. PATENT & TRADEMARK OFFICE  
RECEIVED

**INFORMATION DISCLOSURE STATEMENT**

Applicant : Cowing  
App. No. : 09/809,158  
Filed : March 15, 2001  
For : METHOD TO ENHANCE THE  
IMMUNOGENICITY OF AN ANTIGEN  
Examiner : Canella, K.  
Group Art Unit : 1642

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 3 references that are also enclosed.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(c)(2) before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

12/17/2003 HALI11 00000023 09809158

02 FC:1806

180.00 OP

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 12/11/03

By: Mark R. Benedict

Mark R. Benedict  
Registration No. 44,531  
Attorney of Record  
Customer No. 20,995  
(949) 760-0404

<p style="text-align: right;">DEC 15 2003 U.S. PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)</p>	ATTY. DOCKET NO. LANCELL.002CP1	APPLICATION NO. 09/809,158
	APPLICANT Cowling	
	FILING DATE March 15, 2001	GROUP 1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
				YES	NO	TRANSLATION	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
KAC	1.	Koyama et al. (1989) Effect of systemic and topical application of testosterone propionate on the density of epidermal Langerhans cells in the mouse. J. Invest. Dermatol. 1:86-90 (Abstract).
KAC	2.	Murphy et al. (1998) Tropical tretinoin replenishes CD1a-positive epidermal Langerhans cells in chronically photodamaged human skin. J. Cutan. Pathol. 1:30-4 (Abstract).
KAC	3.	Ragg et al. (1994) Lagerhans cell migration patterns from sheep skin following topical application of carcinogens. Int. J. Exp. Pathol. 1:23-8.

O:\DOCS\MXG\MXG-4192.DOC:vb  
121003

EXAMINER	/Karen A. Canella, Ph.D./	DATE CONSIDERED	10/02/2006
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			